{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T06:30:33Z","timestamp":1785306633414,"version":"3.55.0"},"reference-count":42,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2025,6,19]],"date-time":"2025-06-19T00:00:00Z","timestamp":1750291200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007771","name":"Medical University of Silesia in Katowice","doi-asserted-by":"publisher","award":["BNW-1-157\/N\/4\/K"],"award-info":[{"award-number":["BNW-1-157\/N\/4\/K"]}],"id":[{"id":"10.13039\/100007771","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) is a leading cause of liver cirrhosis, with its global prevalence rising due to obesity, insulin resistance, and type 2 diabetes mellitus. While bariatric surgery remains effective for weight loss, Glucagon-Like Peptide-1 analogs such as liraglutide are emerging as promising pharmacological treatments. This study aimed to evaluate the effects of a 3-month liraglutide treatment on liver steatosis, subclinical markers, and insulin resistance in non-diabetic, obese patients with MASLD. Twenty-eight obese adults (BMI \u2265 30 kg\/m2) were treated with daily subcutaneous liraglutide injections for three months. Liver steatosis was assessed using FibroScan\u00ae (CAP score) and non-invasive indices (Hepatic Steatosis Index\u2014HSI, and NAFLD Liver Fat Score\u2014NLFS). Insulin resistance was measured with conventional markers (HOMA-IR, QUICKI) and triglyceride-based indices (METS-IR, TyG). Liraglutide significantly reduced liver steatosis (CAP score: 305 to 268 dB\/m, p &lt; 0.05) and improved HSI, while NLFS remained unchanged. Despite significant weight loss, traditional insulin resistance markers remained unchanged, while METS-IR and TyG improved. Liraglutide therapy improved liver steatosis and triglyceride-based insulin resistance markers in non-diabetic obese patients with MASLD. These findings support the use of liraglutide, highlighting the value of personalized approaches and alternative insulin resistance assessments in MASLD management.<\/jats:p>","DOI":"10.3390\/ijms26125883","type":"journal-article","created":{"date-parts":[[2025,6,19]],"date-time":"2025-06-19T08:43:58Z","timestamp":1750322638000},"page":"5883","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Liraglutide Reduces Liver Steatosis and Improves Metabolic Indices in Obese Patients Without Diabetes: A 3-Month Prospective Study"],"prefix":"10.3390","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1206-8702","authenticated-orcid":false,"given":"Aleksandra","family":"Bo\u0142dys","sequence":"first","affiliation":[{"name":"Department of Internal Medicine and Clinical Pharmacology, Faculty of Medical Sciences in Katowice, Medical University of Silesia, Medyk\u00f3w 18, 40-752 Katowice, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2017-5516","authenticated-orcid":false,"given":"\u0141ukasz","family":"Bu\u0142dak","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Clinical Pharmacology, Faculty of Medical Sciences in Katowice, Medical University of Silesia, Medyk\u00f3w 18, 40-752 Katowice, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Micha\u0142","family":"Nicze","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Clinical Pharmacology, Faculty of Medical Sciences in Katowice, Medical University of Silesia, Medyk\u00f3w 18, 40-752 Katowice, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7228-2906","authenticated-orcid":false,"given":"Bogus\u0142aw","family":"Okopie\u0144","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Clinical Pharmacology, Faculty of Medical Sciences in Katowice, Medical University of Silesia, Medyk\u00f3w 18, 40-752 Katowice, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,6,19]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1038\/s41575-023-00759-2","article-title":"Global Epidemiology of Cirrhosis\u2014Aetiology, Trends and Predictions","volume":"20","author":"Huang","year":"2023","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Unalp-Arida, A., and Ruhl, C.E. (2024). Prevalence of Metabolic Dysfunction-Associated Steatotic Liver Disease and Fibrosis Defined by Liver Elastography in the United States Using National Health and Nutrition Examination Survey 2017-March 2020 and August 2021\u2013August 2023 Data. Hepatology.","DOI":"10.1097\/HEP.0000000000001211"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"103043","DOI":"10.1016\/j.arcmed.2024.103043","article-title":"Global Prevalence of Nonalcoholic Fatty Liver Disease: An Updated Review Meta-Analysis Comprising a Population of 78 Million from 38 Countries","volume":"55","author":"Letafatkar","year":"2024","journal-title":"Arch. Med. Res."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1097\/HEP.0000000000000004","article-title":"The Global Epidemiology of Nonalcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH): A Systematic Review","volume":"77","author":"Younossi","year":"2023","journal-title":"Hepatology"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"e00806","DOI":"10.14309\/ctg.0000000000000806","article-title":"Healthy Lifestyle and Metabolic Dysfunction-Associated Steatotic Liver Disease: A Study of the Efficacy of Fatty Liver Regression","volume":"16","author":"Wang","year":"2025","journal-title":"Clin. Transl. Gastroenterol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"111969","DOI":"10.1016\/j.diabres.2024.111969","article-title":"The Journey of MASLD: Tracking Resolution, Relapse, and Predictive Factors after Sleeve Gastrectomy and One-Anastomosis Gastric Bypass, a Propensity Score-Matched Cohort Study","volume":"219","author":"Sadeghi","year":"2025","journal-title":"Diabetes Res. Clin. Pract."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Mart\u00ednez-Montoro, J.I., Arranz-Salas, I., Guti\u00e9rrez-Repiso, C., S\u00e1nchez-Garc\u00eda, A., Oca\u00f1a-Wilhelmi, L., Pinazo-Bandera, J.M., Fern\u00e1ndez-Garc\u00eda, D., Mu\u00f1oz-Garach, A., Morales-Garc\u00eda, D., and Garc\u00eda-Cort\u00e9s, M. (2024). Weight Loss After Sleeve Gastrectomy According to Metabolic Dysfunction-Associated Steatotic Liver Disease Stage in Patients with Obesity: A Liver Biopsy-Based Prospective Study. Nutrients, 16.","DOI":"10.3390\/nu16223857"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"3963","DOI":"10.1007\/s11695-024-07370-7","article-title":"Scientific Evidence for the Updated Guidelines on Indications for Metabolic and Bariatric Surgery (IFSO\/ASMBS)","volume":"34","author":"Shikora","year":"2024","journal-title":"Obes. Surg."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"196","DOI":"10.31128\/AJGP-09-24-7411","article-title":"Pharmacotherapy for the Management of Overweight and Obesity","volume":"54","author":"Forner","year":"2025","journal-title":"Aust. J. Gen. Pract."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"8316","DOI":"10.36922\/imo.8316","article-title":"Obesity Management: An Update on the Available Pharmacotherapy","volume":"2","author":"Christaki","year":"2025","journal-title":"Innov. Med. Omics"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1136\/gutjnl-2024-334023","article-title":"Recent Advances in Incretin-Based Therapy for MASLD: From Single to Dual or Triple Incretin Receptor Agonists","volume":"74","author":"Targher","year":"2025","journal-title":"Gut"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"419","DOI":"10.5603\/ep.99891","article-title":"The Impact of Glucagon and Exenatide on Oxidative Stress Levels and Antioxidative Enzyme Expression in in Vitro Induced Steatosis in HepG2 Cell Culture","volume":"75","author":"Skudrzyk","year":"2024","journal-title":"Endokrynol. Pol."},{"key":"ref_13","first-page":"e20776","article-title":"Factors That Predict the Progression of Non-Alcoholic Fatty Liver Disease (NAFLD)","volume":"13","author":"Parameswaran","year":"2021","journal-title":"Cureus"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.gastrohep.2023.10.005","article-title":"Risk Factors for Fibrosis Progression in Non-Alcoholic Steatohepatitis: Analysis of the European Cohort in the Real-World GAIN Study","volume":"47","author":"Shaikh","year":"2024","journal-title":"Gastroenterol. Y Hepatol."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Yanai, H., Adachi, H., Hakoshima, M., Iida, S., and Katsuyama, H. (2023). Metabolic-Dysfunction-Associated Steatotic Liver Disease-Its Pathophysiology, Association with Atherosclerosis and Cardiovascular Disease, and Treatments. Int. J. Mol. Sci., 24.","DOI":"10.20944\/preprints202309.1062.v1"},{"key":"ref_16","first-page":"323","article-title":"Management of Patients with Non-Alcoholic Fatty Liver Disease (NAFLD)\u2014Recommendations for General Practitioners. Based on the Guidelines of the Polish Group of Experts on NAFLD","volume":"5","author":"Hartleb","year":"2019","journal-title":"Lek. POZ"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"153","DOI":"10.5114\/ceh.2018.78118","article-title":"Recommendations for the Management of Non-Alcoholic Fatty Liver Disease (NAFLD)","volume":"4","author":"Tomasiewicz","year":"2018","journal-title":"Clin. Exp. Hepatol."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Wang, W., Huang, L., Qiu, X.P., Tu, M., and Guo, X.L. (2024). Monocytes to Apolipoprotein A1 Ratio Is Associated with Metabolic Dysfunction-Associated Fatty Liver Disease in Type 2 Diabetes Mellitus. Sci. Rep., 14.","DOI":"10.1038\/s41598-024-82994-4"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.jacl.2015.11.017","article-title":"The Associations between Apolipoprotein B, A1, and the B\/A1 Ratio and Nonalcoholic Fatty Liver Disease in Both Normal-Weight and Overweight Korean Population","volume":"10","author":"Yang","year":"2016","journal-title":"J. Clin. Lipidol."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Aktary, M.L., Eller, L.K., Nicolucci, A.C., and Reimer, R.A. (2020). Cross-Sectional Analysis of the Health Profile and Dietary Intake of a Sample of Canadian Adults Diagnosed with Non-Alcoholic Fatty Liver Disease. Food Nutr. Res., 64.","DOI":"10.29219\/fnr.v64.4548"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"bvae122","DOI":"10.1210\/jendso\/bvae122","article-title":"Semaglutide Concurrently Improves Vascular and Liver Indices in Patients With Type 2 Diabetes and Fatty Liver Disease","volume":"8","author":"Korakas","year":"2024","journal-title":"J. Endocr. Soc."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Nixdorf, L., Hartl, L., Str\u00f6hl, S., Felsenreich, D.M., Mairinger, M., Jedamzik, J., Richwien, P., Mozayani, B., Semmler, G., and Balcar, L. (2024). Rapid Improvement of Hepatic Steatosis and Liver Stiffness after Metabolic\/Bariatric Surgery: A Prospective Study. Sci. Rep., 14.","DOI":"10.1038\/s41598-024-67415-w"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"e4192","DOI":"10.1210\/clinem\/dgab255","article-title":"Foregut Exclusion Enhances Incretin and Insulin Secretion After Roux-En-Y Gastric Bypass in Adults With Type 2 Diabetes","volume":"106","author":"Kirwan","year":"2021","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"100033","DOI":"10.4254\/wjh.v17.i2.100033","article-title":"Modern Ultrasound Techniques for Diagnosing Liver Steatosis and Fibrosis: A Systematic Review with a Focus on Biopsy Comparison","volume":"17","author":"Pozowski","year":"2025","journal-title":"World J. Hepatol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1002\/jmri.23741","article-title":"Proton Density Fat\u2014Fraction: A Standardized Mr\u2014Based Biomarker of Tissue Fat Concentration","volume":"36","author":"Reeder","year":"2012","journal-title":"Magn. Reson. Imaging"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1097\/HEP.0000000000000323","article-title":"AASLD Practice Guidance on the Clinical Assessment and Management of Nonalcoholic Fatty Liver Disease","volume":"77","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Tudor, M.S., Gheorman, V., Simeanu, G.-M., Dobrinescu, A., P\u0103dureanu, V., Dinescu, V.C., and For\u021bofoiu, M.-C. (2024). Evolutive Models, Algorithms and Predictive Parameters for the Progression of Hepatic Steatosis. Metabolites, 14.","DOI":"10.3390\/metabo14040198"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), and European Association for the Study of Obesity (EASO) (2024). EASL-EASD-EASO Clinical Practice Guidelines on the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD). Obes. Facts, 17, 374\u2013444.","DOI":"10.1159\/000539371"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"130","DOI":"10.32725\/jab.2022.015","article-title":"Exenatide Prevents Statin-Related LDL Receptor Increase and Improves Insulin Secretion in Pancreatic Beta Cells (1.1E7) in a Protein Kinase A-Dependent Manner","volume":"20","author":"Buldak","year":"2022","journal-title":"J. Appl. Biomed."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/s41392-024-01931-z","article-title":"Glucagon-like Peptide-1 Receptor: Mechanisms and Advances in Therapy","volume":"9","author":"Zheng","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"38","DOI":"10.2337\/db23-0356","article-title":"Weight Loss-Independent Effect of Liraglutide on Insulin Sensitivity in Individuals With Obesity and Prediabetes","volume":"73","author":"Mashayekhi","year":"2024","journal-title":"Diabetes"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1080\/03007995.2024.2442027","article-title":"Glucagon-like Peptide 1 Receptor Agonists Modestly Reduced Low-Density Lipoprotein Cholesterol and Total Cholesterol Levels Independent of Weight Reduction: A Meta-Analysis and Meta-Regression of Placebo Controlled Randomized Controlled Trials","volume":"41","author":"Rivera","year":"2025","journal-title":"Curr. Med. Res. Opin."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s12933-024-02140-2","article-title":"Revisiting an Old Relationship: The Causal Associations of the ApoB\/ApoA1 Ratio with Cardiometabolic Diseases and Relative Risk Factors-a Mendelian Randomization Analysis","volume":"23","author":"Fu","year":"2024","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Wang, W., Chen, Y., Tu, M., and Chen, H.J. (2024). Triglycerides to Apolipoprotein A1 Ratio: An Effective Insulin Resistance-Associated Index in Identifying Metabolic Dysfunction-Associated Fatty Liver Disease in Type 2 Diabetes Mellitus. Front. Endocrinol., 15.","DOI":"10.3389\/fendo.2024.1384059"},{"key":"ref_35","first-page":"e70768","article-title":"Understanding Insulin Resistance in NAFLD: A Systematic Review and Meta-Analysis Focused on HOMA-IR in South Asians","volume":"16","author":"Mehta","year":"2024","journal-title":"Cureus"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"102581","DOI":"10.1016\/j.dsx.2022.102581","article-title":"Challenges in the Diagnosis of Insulin Resistance: Focusing on the Role of HOMA-IR and Tryglyceride\/Glucose Index","volume":"16","author":"Tahapary","year":"2022","journal-title":"Diabetes Metab. Syndr."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1111\/jch.14155","article-title":"Assessment of Preferred Methods to Measure Insulin Resistance in Asian Patients with Hypertension","volume":"23","author":"Minh","year":"2021","journal-title":"J. Clin. Hypertens."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1186\/s12933-024-02334-8","article-title":"Metabolic Score for Insulin Resistance (METS-IR) Predicts All-Cause and Cardiovascular Mortality in the General Population: Evidence from NHANES 2001-2018","volume":"23","author":"Duan","year":"2024","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_39","first-page":"e46623","article-title":"Advances in Anti-Obesity Pharmacotherapy: Current Treatments, Emerging Therapies, and Challenges","volume":"15","author":"Brandfon","year":"2023","journal-title":"Cureus"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"3490","DOI":"10.1111\/dom.16376","article-title":"Adverse Drug Reaction Patterns of GLP --1 Receptor Agonists Approved for Obesity Treatment: Disproportionality Analysis from Global Pharmacovigilance Database","volume":"27","author":"Kim","year":"2025","journal-title":"Diabetes Obes. Metab."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1053\/j.gastro.2009.06.005","article-title":"Prediction of Non-Alcoholic Fatty Liver Disease and Liver Fat Using Metabolic and Genetic Factors","volume":"137","author":"Kotronen","year":"2009","journal-title":"Gastroenterology"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/s12944-021-01561-2","article-title":"The Usefulness of Obesity and Lipid-Related Indices to Predict the Presence of Non-Alcoholic Fatty Liver Disease","volume":"20","author":"Sheng","year":"2021","journal-title":"Lipids Health Dis."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/12\/5883\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:55:01Z","timestamp":1760032501000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/12\/5883"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,19]]},"references-count":42,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2025,6]]}},"alternative-id":["ijms26125883"],"URL":"https:\/\/doi.org\/10.3390\/ijms26125883","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,19]]}}}